Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Safety and Efficacy of Adalimumab in Patients With Active Psoriatic Arthritis (PsA) - An Open-Label, Multinational Study to Evaluate the Response to Every-Other Week Adalimumab When Added to Insufficient Standard Therapy, Including Patients Who Failed Prior Treatment With Other TNF-Inhibitors (STEREO)

NCT00235885 is registered in ClinicalTrials.gov with Abbott as lead sponsor.

NCT NCT00235885
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00235885 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Safety and Efficacy of Adalimumab in Patients With Active Psoriatic Arthritis (PsA) - An Open-Label, Multinational Study to Evaluate the Response to Every-Other Week Adalimumab When Added to Insufficient Standard Therapy, Including Patients Who Failed Prior Treatment With Other TNF-Inhibitors (STEREO)
Lead sponsor
Abbott
Phase
Phase 3
Overall status
Completed
Start date
July 31, 2005
Completion date
Not reported
Enrollment
445
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

psoriatic arthritis